| --- | --- | |-------|-------| | | | | | | Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Silence Therapeutics FY20 Results March 30, 2021 Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any su ...

Silence Therapeutics plc (NASDAQ:SLN) Q4 2020 Results Earnings Conference Call March 30, 2021 8:00 AM ET Company Participants Gem Hopkins - Head, Investor Relations and Corporate Communications Mark Rothera - President and CEO Craig Tooman - Chief Financial Officer Dr. Giles Campion - Head, R&D and CMO Conference Call Participants Julian Harrison - BTIG Patrick Trucchio - H.C. Wainwright Miles Dixon - Peel Hunt Myles Minter - William Blair Operator Good day, ladies and gentlemen. And welcome to the Silence ...

Silence Therapeutics Plc (OTC:SLNCF) Q2 2020 Results Conference Call September 14, 2020 8:00 AM ET Company Participants Gem Hopkins - Head, IR and Corporate Communications Iain Ross - Chairman Mark Rothera - President & CEO Giles Campion - Head of R&D and Chief Medical Officer Rob Quinn - Chief Financial Officer Conference Call Participants Patrick Trucchio - H.C. Wainwright Jens Lindqvist - Investec Miles Dixon - Peel Hunt Gem Hopkins Good morning and good afternoon, and thank you for joining us for the Si ...

Silence Therapeutics H1 2020 Results September 14, 2020 Forward Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, a ...

Silence Therapeutics plc (OTC:SLNCF) Q4 2019 Earnings Conference Call April 14, 2020 8:00 AM ET Company Participants Iain Ross – Interim Executive Chairman Rob Quinn – Chief Financial Officer Giles Campion – Head-R&D and Chief Medical Officer Conference Call Participants Miles Dixon – Peel Hunt Nathaniel Calloway – Edison Group Jens Lindqvist – Investec Iain Ross Hi, good afternoon, everybody. IÂ'm very pleased to be able to present the 2019 results for Silence Therapeutics. I think this is quite an extraor ...

Silence Therapeutics PLC (OTC:SLNCF) Q4 2018 Earnings Conference Call March 11, 2019 8:00 AM ET Company Participants Dr. David Horn Solomon - President and CEO Rob Quinn - Interim CFO Conference Call Participants Miles Dixon - Peel Hunt LLP Operator Ladies and gentlemen, thank you for standing by. Welcome to the Full Year Results for the Year Ended 31st December 2018. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session [Operator In ...

Full Year Results 2018 Presentation 11 March 2019 Disclaimer (US) The information contained in this presentation is being supplied and communicated to you on a confidential basis solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and obs ...